Loading…

LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity

High rates of unintended pregnancies worldwide indicate a need for more accessible and acceptable methods of contraception. We have developed a monoclonal antibody, the Human Contraception Antibody (HCA), for use by women in vaginal films and rings for contraception. The divalent F(ab')2 region...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-01, Vol.18 (3), p.e0282147
Main Authors: Emilie Mausser, Ellena Nador, Joseph A Politch, Michael R Pauly, Jai G Marathe, Thomas R Moench, Larry Zeitlin, Kevin J Whaley, Deborah J Anderson
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page e0282147
container_title PloS one
container_volume 18
creator Emilie Mausser
Ellena Nador
Joseph A Politch
Michael R Pauly
Jai G Marathe
Thomas R Moench
Larry Zeitlin
Kevin J Whaley
Deborah J Anderson
description High rates of unintended pregnancies worldwide indicate a need for more accessible and acceptable methods of contraception. We have developed a monoclonal antibody, the Human Contraception Antibody (HCA), for use by women in vaginal films and rings for contraception. The divalent F(ab')2 region of HCA binds to an abundant male reproductive tract-specific antigen, CD52g, and potently agglutinates sperm. Certain other antibody activities mediated by the Fc region such as mucus trapping, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) could have beneficial or negative effects. The purpose of this study was to document HCA Fc effector functions and determine whether an engineered variant of HCA with a modified Fc region, HCA-LALAPG, retains desirable contraceptive activity while minimizing Fc-mediated effects. Fab and Fc functions were compared between HCA and HCA-LALAPG. Fab activity was assessed using sperm agglutination and modified swim-up ("sperm escape") assays. Fc functions were assessed by CDC (sperm immobilization), ADCP, and cervical mucus penetration assays. HCA and HCA-LALAPG showed equivalent activity in assays of Fab function. In the assays of Fc function, HCA supported strong CDC, ADCP, and sperm trapping in cervical mucus whereas HCA-LALAPG demonstrated little to no activity. HCA and the HCA-LALAPG variant were both highly effective in the sperm agglutination assays but differed in Fc mediated functions. Use of the HCA-LALAPG variant for contraception in women could reduce antibody-mediated inflammation and antigen presentation but may have reduced contraceptive efficacy due to much weaker sperm trapping in mucus and complement-dependent sperm immobilization activity.
doi_str_mv 10.1371/journal.pone.0282147
format article
fullrecord <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_be5acf215cfe4c2b96bdb4513195bae6</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_be5acf215cfe4c2b96bdb4513195bae6</doaj_id><sourcerecordid>oai_doaj_org_article_be5acf215cfe4c2b96bdb4513195bae6</sourcerecordid><originalsourceid>FETCH-doaj_primary_oai_doaj_org_article_be5acf215cfe4c2b96bdb4513195bae63</originalsourceid><addsrcrecordid>eNqtjM1KxDAUhYMgOP68gYu71EVr07-ZLktxrDALF-7LTXrTSWmTkqYjfQmf2XHwEVwcDhy-8zH2yKOQJ1v-0tvFGRzCyRoKo3gX83R7xTa8SOIgj6Pkht3Ocx9FWbLL8w37PpSH8uMNTug0Gg9WgT8S1MuIBiprvENJk9fWQGm8FrZd4amuymdw1C6SZtjLYKRWo6cWSCmS3jpQi5G_pxm-jnogGFEbf442HcwTuRGw64bFa4MXN57pk_brPbtWOMz08Nd37H3_-lnVQWuxbyanR3RrY1E3l8G6rkHntRyoEZShVDHPpKJUxqLIRSvSjCe8yARSnvyn6wctUniu</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><creator>Emilie Mausser ; Ellena Nador ; Joseph A Politch ; Michael R Pauly ; Jai G Marathe ; Thomas R Moench ; Larry Zeitlin ; Kevin J Whaley ; Deborah J Anderson</creator><creatorcontrib>Emilie Mausser ; Ellena Nador ; Joseph A Politch ; Michael R Pauly ; Jai G Marathe ; Thomas R Moench ; Larry Zeitlin ; Kevin J Whaley ; Deborah J Anderson</creatorcontrib><description>High rates of unintended pregnancies worldwide indicate a need for more accessible and acceptable methods of contraception. We have developed a monoclonal antibody, the Human Contraception Antibody (HCA), for use by women in vaginal films and rings for contraception. The divalent F(ab')2 region of HCA binds to an abundant male reproductive tract-specific antigen, CD52g, and potently agglutinates sperm. Certain other antibody activities mediated by the Fc region such as mucus trapping, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) could have beneficial or negative effects. The purpose of this study was to document HCA Fc effector functions and determine whether an engineered variant of HCA with a modified Fc region, HCA-LALAPG, retains desirable contraceptive activity while minimizing Fc-mediated effects. Fab and Fc functions were compared between HCA and HCA-LALAPG. Fab activity was assessed using sperm agglutination and modified swim-up ("sperm escape") assays. Fc functions were assessed by CDC (sperm immobilization), ADCP, and cervical mucus penetration assays. HCA and HCA-LALAPG showed equivalent activity in assays of Fab function. In the assays of Fc function, HCA supported strong CDC, ADCP, and sperm trapping in cervical mucus whereas HCA-LALAPG demonstrated little to no activity. HCA and the HCA-LALAPG variant were both highly effective in the sperm agglutination assays but differed in Fc mediated functions. Use of the HCA-LALAPG variant for contraception in women could reduce antibody-mediated inflammation and antigen presentation but may have reduced contraceptive efficacy due to much weaker sperm trapping in mucus and complement-dependent sperm immobilization activity.</description><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0282147</identifier><language>eng</language><publisher>Public Library of Science (PLoS)</publisher><ispartof>PloS one, 2023-01, Vol.18 (3), p.e0282147</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Emilie Mausser</creatorcontrib><creatorcontrib>Ellena Nador</creatorcontrib><creatorcontrib>Joseph A Politch</creatorcontrib><creatorcontrib>Michael R Pauly</creatorcontrib><creatorcontrib>Jai G Marathe</creatorcontrib><creatorcontrib>Thomas R Moench</creatorcontrib><creatorcontrib>Larry Zeitlin</creatorcontrib><creatorcontrib>Kevin J Whaley</creatorcontrib><creatorcontrib>Deborah J Anderson</creatorcontrib><title>LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity</title><title>PloS one</title><description>High rates of unintended pregnancies worldwide indicate a need for more accessible and acceptable methods of contraception. We have developed a monoclonal antibody, the Human Contraception Antibody (HCA), for use by women in vaginal films and rings for contraception. The divalent F(ab')2 region of HCA binds to an abundant male reproductive tract-specific antigen, CD52g, and potently agglutinates sperm. Certain other antibody activities mediated by the Fc region such as mucus trapping, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) could have beneficial or negative effects. The purpose of this study was to document HCA Fc effector functions and determine whether an engineered variant of HCA with a modified Fc region, HCA-LALAPG, retains desirable contraceptive activity while minimizing Fc-mediated effects. Fab and Fc functions were compared between HCA and HCA-LALAPG. Fab activity was assessed using sperm agglutination and modified swim-up ("sperm escape") assays. Fc functions were assessed by CDC (sperm immobilization), ADCP, and cervical mucus penetration assays. HCA and HCA-LALAPG showed equivalent activity in assays of Fab function. In the assays of Fc function, HCA supported strong CDC, ADCP, and sperm trapping in cervical mucus whereas HCA-LALAPG demonstrated little to no activity. HCA and the HCA-LALAPG variant were both highly effective in the sperm agglutination assays but differed in Fc mediated functions. Use of the HCA-LALAPG variant for contraception in women could reduce antibody-mediated inflammation and antigen presentation but may have reduced contraceptive efficacy due to much weaker sperm trapping in mucus and complement-dependent sperm immobilization activity.</description><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqtjM1KxDAUhYMgOP68gYu71EVr07-ZLktxrDALF-7LTXrTSWmTkqYjfQmf2XHwEVwcDhy-8zH2yKOQJ1v-0tvFGRzCyRoKo3gX83R7xTa8SOIgj6Pkht3Ocx9FWbLL8w37PpSH8uMNTug0Gg9WgT8S1MuIBiprvENJk9fWQGm8FrZd4amuymdw1C6SZtjLYKRWo6cWSCmS3jpQi5G_pxm-jnogGFEbf442HcwTuRGw64bFa4MXN57pk_brPbtWOMz08Nd37H3_-lnVQWuxbyanR3RrY1E3l8G6rkHntRyoEZShVDHPpKJUxqLIRSvSjCe8yARSnvyn6wctUniu</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Emilie Mausser</creator><creator>Ellena Nador</creator><creator>Joseph A Politch</creator><creator>Michael R Pauly</creator><creator>Jai G Marathe</creator><creator>Thomas R Moench</creator><creator>Larry Zeitlin</creator><creator>Kevin J Whaley</creator><creator>Deborah J Anderson</creator><general>Public Library of Science (PLoS)</general><scope>DOA</scope></search><sort><creationdate>20230101</creationdate><title>LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity</title><author>Emilie Mausser ; Ellena Nador ; Joseph A Politch ; Michael R Pauly ; Jai G Marathe ; Thomas R Moench ; Larry Zeitlin ; Kevin J Whaley ; Deborah J Anderson</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-doaj_primary_oai_doaj_org_article_be5acf215cfe4c2b96bdb4513195bae63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Emilie Mausser</creatorcontrib><creatorcontrib>Ellena Nador</creatorcontrib><creatorcontrib>Joseph A Politch</creatorcontrib><creatorcontrib>Michael R Pauly</creatorcontrib><creatorcontrib>Jai G Marathe</creatorcontrib><creatorcontrib>Thomas R Moench</creatorcontrib><creatorcontrib>Larry Zeitlin</creatorcontrib><creatorcontrib>Kevin J Whaley</creatorcontrib><creatorcontrib>Deborah J Anderson</creatorcontrib><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Emilie Mausser</au><au>Ellena Nador</au><au>Joseph A Politch</au><au>Michael R Pauly</au><au>Jai G Marathe</au><au>Thomas R Moench</au><au>Larry Zeitlin</au><au>Kevin J Whaley</au><au>Deborah J Anderson</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity</atitle><jtitle>PloS one</jtitle><date>2023-01-01</date><risdate>2023</risdate><volume>18</volume><issue>3</issue><spage>e0282147</spage><pages>e0282147-</pages><eissn>1932-6203</eissn><abstract>High rates of unintended pregnancies worldwide indicate a need for more accessible and acceptable methods of contraception. We have developed a monoclonal antibody, the Human Contraception Antibody (HCA), for use by women in vaginal films and rings for contraception. The divalent F(ab')2 region of HCA binds to an abundant male reproductive tract-specific antigen, CD52g, and potently agglutinates sperm. Certain other antibody activities mediated by the Fc region such as mucus trapping, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) could have beneficial or negative effects. The purpose of this study was to document HCA Fc effector functions and determine whether an engineered variant of HCA with a modified Fc region, HCA-LALAPG, retains desirable contraceptive activity while minimizing Fc-mediated effects. Fab and Fc functions were compared between HCA and HCA-LALAPG. Fab activity was assessed using sperm agglutination and modified swim-up ("sperm escape") assays. Fc functions were assessed by CDC (sperm immobilization), ADCP, and cervical mucus penetration assays. HCA and HCA-LALAPG showed equivalent activity in assays of Fab function. In the assays of Fc function, HCA supported strong CDC, ADCP, and sperm trapping in cervical mucus whereas HCA-LALAPG demonstrated little to no activity. HCA and the HCA-LALAPG variant were both highly effective in the sperm agglutination assays but differed in Fc mediated functions. Use of the HCA-LALAPG variant for contraception in women could reduce antibody-mediated inflammation and antigen presentation but may have reduced contraceptive efficacy due to much weaker sperm trapping in mucus and complement-dependent sperm immobilization activity.</abstract><pub>Public Library of Science (PLoS)</pub><doi>10.1371/journal.pone.0282147</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1932-6203
ispartof PloS one, 2023-01, Vol.18 (3), p.e0282147
issn 1932-6203
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_be5acf215cfe4c2b96bdb4513195bae6
source Publicly Available Content Database; PubMed Central(OpenAccess)
title LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T17%3A05%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LALAPG%20variant%20of%20the%20Human%20Contraception%20Antibody%20(HCA)%20reduces%20Fc-mediated%20effector%20functions%20while%20maintaining%20sperm%20agglutination%20activity&rft.jtitle=PloS%20one&rft.au=Emilie%20Mausser&rft.date=2023-01-01&rft.volume=18&rft.issue=3&rft.spage=e0282147&rft.pages=e0282147-&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0282147&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_be5acf215cfe4c2b96bdb4513195bae6%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-doaj_primary_oai_doaj_org_article_be5acf215cfe4c2b96bdb4513195bae63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true